iwMyeloma 2022 | Novel Targets: PIKfyve, RAS, the epigenome & PROTAC therapy
Lawrence Boise and Paola Neri
• 27 Mar 2022
In this session, we take a look at the very latest in novel targets. The experts discuss introducing a pro-survival gene into CARs, targeting RAS, PIKfyve, and epigenomics, the epigenetics of resistance to proteasome and IMiD drugs as well as PROTAC therapy for difficult manipulate targets. Lawrence Boise, PhD, Winship Cancer Institute of Emory University, Atlanta, GA, chairs this session with Paola Neri, MD, PhD, University of Calgary, Calgary, Canada. This discussion took place at The International Workshop on Myeloma 2022, held in Scottsdale, AZ.
